Posts by: Marisa Wexler, MS

Marisa Wexler, MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

December 21, 2020December 21, 2020

Sex Differences Found in nr-axSpA Disease Severity, Treatment Response

News

Among people with non-radiographic axial spondyloarthritis (nr-axSpA) — a type of arthritis that mainly affects the joints of the spine — women tend to have more severe disease than ... Read more

November 16, 2020November 16, 2020

Clinical Trial Data Show Durable Efficacy of Cimzia, Bimekizumab

News

Treatment with Cimzia (certolizumab pegol) can ease eye inflammation in people with ankylosing spondylitis (AS), and reduce symptoms in those with active non-radiographic axial spondyloarthritis (nr-axSpA), new clinical trial data ... Read more

November 9, 2020November 9, 2020

Xeljanz Eases AS Symptoms in Phase 3 Trial

News

Treatment with Xeljanz (tofacitinib) was found to significantly ease symptoms of ankylosing spondylitis (AS) in a Phase 3 clinical trial. The results are being presented today at ACR Convergence ... Read more

November 5, 2020November 6, 2020

NORD Hosting ‘RareLaunch’ Workshops to Help Start Rare Disease Non-profits

News, syndicated

The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit ... Read more

October 26, 2020October 26, 2020

Humira Boosts Work Productivity, Lessens Sleep Problems in AS, Study Finds

News

Treatment with Humira (adalimumab) increases work productivity, reduces sleep problems, and eases disease activity in people with ankylosing spondylitis (AS) and related diseases, a new real-world study indicates. The ... Read more

October 21, 2020October 21, 2020

Telehealth ‘Helpful’ Alternative to In-person Care, Rare Disease Patients Say

News, syndicated

A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a ... Read more

October 12, 2020October 12, 2020

AS Pain Linked With Depression, Anxiety, Stress, Study Finds

News

People with ankylosing spondylitis (AS) often endure considerable psychological distress — including depression, anxiety, and stress — that is related to their experience of pain, a study shows. These ... Read more

September 28, 2020September 28, 2020

Study Supports Efficacy of Cosentyx for Patients in China, Other Countries

News

Cosentyx (secukinumab) is a safe and effective treatment for ankylosing spondylitis (AS), producing similar results in Chinese patients compared to other populations, a Phase 3 study indicates. The study, ... Read more

August 31, 2020August 31, 2020

AbbVie Seeks FDA, EMA Approvals of Rinvoq for Active AS

News

AbbVie has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of Rinvoq (upadacitinib) for the treatment of adults with active ankylosing spondylitis (AS). ... Read more

July 29, 2020July 29, 2020

EU Approves Under-the-skin Remsima Injectable for 5 Autoimmune Disorders

News

An under-the-skin injectable formulation of Remsima (infliximab), called Remsima SC, has been approved in European Union for the treatment of five autoimmune disorders, including ankylosing spondylitis. The approval by the European ... Read more